Taking a weekly injection called semaglutide along with healthy eating and exercise can help people with obesity or overweight lose about 15% of their body weight in a year—much more than people who just take a sugar pill.
See the scientific wording
Once-weekly subcutaneous semaglutide at a dose of 2.4 mg, when combined with lifestyle intervention, results in an average weight loss of 14.9% to 16.0% over 68 weeks in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with comorbidities, and this weight loss is significantly greater than the 2.4% to 5.7% weight loss observed with placebo.
Correlational — new studies may shift this
One low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Once-Weekly Semaglutide for Weight Management: A Clinical Review
Narrative ReviewReview2022
This study says that a weekly shot called semaglutide, when paired with eating better and exercising, helps people lose a lot of weight — just like the claim says. It doesn’t give the exact numbers here, but it points to big studies that did, so it backs up the claim.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Taking a weekly injection called semaglutide along with healthy eating and exercise can help people with obesity or overweight lose about 15% of their body weight in a year—much more than people who just take a sugar pill.
Evidence from Studies
Supporting (1)
Community contributions welcome
Once-Weekly Semaglutide for Weight Management: A Clinical Review
This study says that a weekly shot called semaglutide, when paired with eating better and exercising, helps people lose a lot of weight — just like the claim says. It doesn’t give the exact numbers here, but it points to big studies that did, so it backs up the claim.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Once-Weekly Semaglutide 2.4 mg Plus Lifestyle Intervention vs Placebo for Weight Loss in Adults with Obesity or Overweight with Comorbidities
Systematic review and meta-analysis of randomized controlled trials comparing semaglutide 2.4 mg SC weekly + lifestyle intervention versus placebo + lifestyle intervention in adults with BMI ≥27 kg/m² and comorbidities, with weight loss percentage as primary outcome at 68 weeks.
Double-Blind, Placebo-Controlled Trial of Once-Weekly Semaglutide 2.4 mg Plus Lifestyle Intervention for Weight Loss in Adults with Obesity or Overweight with Comorbidities Over 68 Weeks
Parallel-group, double-blind, placebo-controlled RCT with 1:1 randomization of adults (BMI ≥27 kg/m² with comorbidities) to semaglutide 2.4 mg SC weekly + lifestyle intervention or placebo SC weekly + identical lifestyle intervention, primary outcome: % weight loss at 68 weeks.
Prospective Cohort Study of Weight Loss Outcomes in Adults Receiving Once-Weekly Semaglutide 2.4 mg with Lifestyle Intervention Compared to Non-Users Over 68 Weeks
Prospective cohort study following adults with BMI ≥27 kg/m² and comorbidities who initiate semaglutide 2.4 mg weekly + lifestyle intervention versus matched controls who do not, measuring % weight loss at 68 weeks with adjustment for baseline BMI, age, sex, and comorbidities.
Case-Control Study Comparing Weight Loss in Adults Achieving ≥15% Weight Loss with Semaglutide 2.4 mg Plus Lifestyle vs. Those Achieving <5% Weight Loss Without It
Case-control study identifying adults who achieved ≥15% weight loss over 68 weeks (cases) and those who lost <5% (controls), then retrospectively comparing exposure to semaglutide 2.4 mg SC weekly + lifestyle intervention.
Cross-Sectional Survey of Weight Loss and Semaglutide Use in Adults with Obesity or Overweight with Comorbidities at a Single Time Point
Cross-sectional survey of adults with BMI ≥27 kg/m² and comorbidities assessing current use of semaglutide 2.4 mg weekly + lifestyle and current % weight loss at a single time point.